Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Phase II clinical trial of isophosphamide (NSC-109724) in patients with advances breast cancer.

× No keyword cloud information.

14 in total

1. Overview of new treatments for breast cancer.

Authors: G N Hortobagyi
Journal: Breast Cancer Res Treat Date: 1992 Impact factor: 4.872

2. A phase II study of intensive-dose epirubicin/verapamil as induction therapy followed by intensive-dose ifosfamide for advanced breast cancer.

Authors: T Langenbuch; K Mross; W Jonat; D K Hossfeld
Journal: Cancer Chemother Pharmacol Date: 1990 Impact factor: 3.333

3. Ifosfamide/etoposide and mesna uroprotection in advanced breast cancer.

Authors: C Manegold; P Worst; J Bickel; H Schmid; P Drings; M Kaufmann
Journal: Cancer Chemother Pharmacol Date: 1990 Impact factor: 3.333

4. High-dose ifosfamide and mesna in advanced breast cancer. A phase II study.

Authors: F Sanchiz; A Milla
Journal: Cancer Chemother Pharmacol Date: 1990 Impact factor: 3.333

5. Docetaxel-ifosfamide combination in patients with HER2-non-overexpressing advanced breast cancer failing prior anthracyclines.

Authors: Christos Kosmas; Nicolas Tsavaris; Nikolaos Malamos; George Tsakonas; Argyris Gassiamis; Aristidis Polyzos; Nicolas Mylonakis; Athanasios Karabelis
Journal: Invest New Drugs Date: 2007-03-17 Impact factor: 3.850

6. Ifosfamide combination chemotherapy in advanced breast cancer.

Authors: H Schmid; M Kaufmann; E M Grischke; G Bastert
Journal: Cancer Chemother Pharmacol Date: 1990 Impact factor: 3.333

7. Epirubicin and ifosfamide in patients with refractory breast cancer and other metastatic solid tumours.

Authors: W Hoffmann; B Weidmann; F Migeod; J Könner; S Seeber
Journal: Cancer Chemother Pharmacol Date: 1990 Impact factor: 3.333

8. Ifosfamide + mitoxantrone in advanced breast cancer previously treated with anthracyclines.

Authors: J Bellmunt; S Morales; M Navarro; L A Solé
Journal: Cancer Chemother Pharmacol Date: 1990 Impact factor: 3.333

9. Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment.

Authors: G Falkson; J J Van Dyk; R Stapelberg; H C Falkson
Journal: Cancer Chemother Pharmacol Date: 1982 Impact factor: 3.333

10. Phase I-II study of docetaxel and ifosfamide combination in patients with anthracycline pretreated advanced breast cancer.

Authors: C Kosmas; N Tsavaris; N Malamos; N Stavroyianni; A Gregoriou; S Rokana; A Polyzos
Journal: Br J Cancer Date: 2003-04-22 Impact factor: 7.640